Regeneron Pharmaceuticals

Get in the Ideas Business.
At Regeneron we believe that when the right idea finds the right team, powerful change is possible.
As we work together to discover, invent, and develop biopharmaceutical medicines, we’re creating whole new ways of thinking about science, manufacturing and commercialization. And whole new ways of thinking about health.
So connect with us. Tell us about you. Learn more about our life-changing medicines. And join us, as we build a future we believe in.

Company Growth (employees)
Tarrytown, US
Size (employees)
5,400 (est)
Regeneron Pharmaceuticals was founded in 1988 and is headquartered in Tarrytown, US

Regeneron Pharmaceuticals Office Locations

Regeneron Pharmaceuticals has offices in Tarrytown, Rensselaer, Bernards, Limerick and in 1 other location
Tarrytown, US (HQ)
777 Old Saw Mill River Rd
Dublin, IE
Harcourt Centre Harcourt St
Bernards, US
110 Allen Rd
Rensselaer, US
81 Columbia Turnpike

Regeneron Pharmaceuticals Metrics

Regeneron Pharmaceuticals Financial Metrics

Revenue (2016)

$4.9 b

Revenue growth (2015-16), %


Gross profit

$4.7 b

Gross profit margin (2016), %


Net income (2016)

$895.5 m

Market capitalization (28-Apr-2017)

$41 b

Closing share price (28-Apr-2017)


Cash (31-Dec-2016)

$535.2 m
Regeneron Pharmaceuticals's current market capitalization is $41 b.
Regeneron Pharmaceuticals's revenue was reported to be $4.9 b in FY, 2016 which is a 18% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$2.1 b$2.8 b$4.1 b$4.9 b

Revenue growth, %


Cost of goods sold

$118 m$129 m$241.7 m$194.6 m

Gross profit

$2 b$2.7 b$3.9 b$4.7 b

Gross profit Margin, %


Operating expense total

$1.2 b$1.9 b$2.6 b$3.5 b


$760 m$838.4 m$1.3 b$1.3 b

EBIT margin, %


Interest expense

$46.4 m$37.4 m$14.2 m$7.2 m

Pre tax profit

$713.4 m$775.7 m$1.2 b$1.3 b

Income tax expense

($289 m)($427.7 m)($589 m)($434.3 m)

Net Income

$424.4 m$348.1 m$636.1 m$895.5 m
FY, 2013FY, 2014FY, 2015FY, 2016


$535.6 m$648.7 m$809.1 m$535.2 m

Accounts Receivable


$70.4 m$128.9 m$238.6 m$399.4 m

Current Assets

$1.8 b$2.2 b$2.9 b$3.2 b


$2.1 b

Total Assets

$3 b$3.9 b$5.6 b$7 b

Accounts Payable

$250.9 m$484.2 m$644.1 m$879.1 m

Current Liabilities

$298.8 m$654.7 m$811.2 m$1.2 b

Common Stock

$2 k$2 k$2 k$2 k

Preferred Stock

Additional Paid-in Capital

$2 b$2.4 b$3.1 b$3 b

Retained Earnings

($92.7 m)$255.4 m$852.7 m$1.7 b

Total Equity

$2 b$2.5 b$3.7 b$4.4 b

Financial Leverage

1.5 x1.5 x1.5 x1.6 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$424.4 m$348.1 m$636.1 m$895.5 m

Depreciation and Amortization

$41.2 m$52.7 m$74.9 m$104.7 m

Accounts Receivable


($48 m)($61 m)($110 m)($150 m)

Accounts Payable

Cash From Operating Activities

$583.6 m$743.2 m$1.3 b$1.5 b

Capital Expenditures

($156.3 m)($333 m)($677.9 m)($511.9 m)

Cash From Investing Activities

($355.5 m)

Cash From Financing Activities

($209.3 m)($262.8 m)($700.4 m)

Interest Paid

$23.8 m$20.6 m$10.6 m$5.5 m

Income Taxes Paid

$59.8 m$276.1 m$481.4 m

Free Cash Flow

$740 m$1.1 b$2 b$2 b

Regeneron Pharmaceuticals Market Value History

Regeneron Pharmaceuticals Median Salaries

Source: 186 public H-1B filings from Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Online Presence

Regeneron Pharmaceuticals News

Regeneron Pharmaceuticals Company Life

You may also be interested in